Latest fatty liver Stories
In contrast to previous preliminary data, use of vitamin E or the diabetes drug metformin was not superior to placebo on a measured outcome for treating nonalcoholic fatty liver disease in children and adolescents.
PARIS, April 22, 2011 /PRNewswire/ -- On the occasion of the 46th Congress of the European Association for the Study of the Liver, the VCTE(TM) (Vibration Controlled Transient Elastography) from Echosens stood out as a leading technique in the field.
Walking on a treadmill for one hour a day may slow the progression of nonalcoholic fatty liver disease in obese people with prediabetes by jump-starting their metabolism and slowing the oxidative damage wrought by the condition.
The meeting Experimental Biology 2011 (EB 2011) begins April 9 and runs through April 13 at the Walter E. Washington Convention Center in Washington, D.C.
Researchers have identified a molecular switch that appears to be a common feature in the development of fatty liver disease.
According to new data presented today at the International Liver CongressTM, the United States (U.S.) could soon be faced with an epidemic of Non-Alcoholic Fatty Liver Disease (NAFLD), one of the major contributing factors of chronic liver disease (CLD), considered as one of the major causes of morbidity and mortality worldwide.
UCLA researchers have demonstrated that a key regulator of cholesterol and fat metabolism in the liver also plays an important role in the development of liver fibrosis â€” the build-up of collagen scar tissue that can develop into cirrhosis.
OSAKA, Japan and NEW YORK, March 30, 2011 /PRNewswire/ -- Dainippon Sumitomo Pharma Co, Ltd. (DSP) and Intercept Pharmaceuticals, Inc.
NEW YORK, March 29, 2011 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., has been informed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health that patient enrollment has started in a new clinical trial in patients with nonalcoholic steatohepatitis (NASH), which will evaluate Intercept's first-in-class farnesoid X receptor (FXR) agonist obeticholic acid (OCA) as a novel therapy for NASH.
NAFLD is a condition where fat accumulates in the liver (steatosis) and can lead to liver inflammation (nonalcoholic steatohepatitis or NASH) and permanent liver damage (fibrosis/cirrhosis).
- A transitional zone between two communities containing the characteristic species of each.